The discovery of such activators would begin with the development of a targeted high-throughput screening (HTS) strategy. This strategy would utilize a library of diverse chemical entities, which would be systematically tested for their ability to increase the activity of gp91phox. The HTS assay would likely be based on the detection of reactive oxygen species or related products that result from the enzymatic action of the NADPH oxidase complex. For instance, a chemiluminescent or fluorescent probe that responds to the presence of these reactive species could be employed. This probe would produce a detectable signal upon reaction with the products of the gp91phox enzyme activity, thus allowing for the rapid identification of compounds that cause an increase in signal intensity above a predefined threshold, indicating potential activator properties.
Subsequently, compounds flagged as potential activators from the HTS process would be further validated through secondary assays. These assays are designed to be more specific and confirm that the increase in enzymatic activity is directly due to the action of the compound on gp91phox. To achieve this, a battery of biochemical assays would be employed to rule out non-specific effects and to ascertain the direct interaction between the compound and the protein. Once confirmed, the interaction between the gp91phox protein and the activator compounds would be characterized in detail. Structural analyses, such as X-ray crystallography or cryo-electron microscopy, could be conducted to reveal the exact nature of the binding and to understand the mechanism by which these activators enhance the protein's activity. Such structural insights would be complemented by kinetic assays that measure changes in the activity rate of the gp91phox protein in the presence of the activators. Additionally, in silico modeling and simulations would play a crucial role in predicting how these activators interact with gp91phox at the molecular level, potentially leading to the rational design of more potent compounds.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC), which plays a pivotal role in the activation of NADPH oxidase. PKC activation leads to the phosphorylation and translocation of p47phox and p67phox to the membrane, where they associate with gp91phox to enhance its activity in the production of reactive oxygen species. | ||||||
Diphenyleneiodonium chloride | 4673-26-1 | sc-202584E sc-202584 sc-202584D sc-202584A sc-202584B sc-202584C | 10 mg 25 mg 50 mg 100 mg 250 mg 500 mg | $151.00 $136.00 $317.00 $405.00 $944.00 $1837.00 | 24 | |
DPI acts as an inhibitor of flavoenzymes and can indirectly enhance the activity of gp91phox by preventing the degradation of NADPH oxidase components, thereby allowing for a sustained respiratory burst in phagocytes. | ||||||
Arachidonic Acid (20:4, n-6) | 506-32-1 | sc-200770 sc-200770A sc-200770B | 100 mg 1 g 25 g | $92.00 $240.00 $4328.00 | 9 | |
Arachidonic acid can activate NADPH oxidase by modulating the activity of PKC and by directly interacting with gp91phox, leading to an increase in its electron transfer activity and the production of superoxide anions. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 increases intracellular calcium concentration, which can activate PKC. Activated PKC then phosphorylates components of the NADPH oxidase complex, such as p47phox, which associates with gp91phox to enhance its activity. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
PGE2 interacts with its receptors to activate adenylate cyclase, increasing intracellular cAMP levels, which activate PKA. PKA phosphorylates cytosolic components of the NADPH oxidase complex, assisting in their translocation to the membrane to activate gp91phox. | ||||||
NOC-18 | 146724-94-9 | sc-202247 sc-202247A sc-202247B sc-202247C | 10 mg 50 mg 100 mg 500 mg | $51.00 $184.00 $305.00 $1122.00 | 18 | |
Nitric oxide donors, such as SNAP, can lead to the modification of critical cysteine residues on NADPH oxidase components, enhancing the assembly and activity of the complex that includes gp91phox, thus promoting the respiratory burst activity. | ||||||
Concanavalin A | 11028-71-0 | sc-203007 sc-203007A sc-203007B | 50 mg 250 mg 1 g | $119.00 $364.00 $947.00 | 17 | |
Concanavalin A is a lectin that can stimulate the aggregation of cell surface receptors, leading to downstream activation of PKC. The activation of PKC results in the phosphorylation of components of the NADPH oxidase complex, enhancing the activity of gp91phox. | ||||||
Zymosan | 9010-72-4 | sc-296863 sc-296863A | 100 mg 1 g | $99.00 $599.00 | 1 | |
Zymosan is a glucan commonly used to stimulate phagocytes, which leads to the activation of PKC and the assembly of the NADPH oxidase complex. The activation of this complex leads to the enhanced activity of gp91phox in producing superoxide anions. | ||||||